Intelligence · Clinical Development
Pipeline search results
Programs matching “air” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 160 pipeline programs matching "air" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D9440C00003
AstraZeneca AB
Healthy Volunteers, Renal Impairment and End Stage Kidney Disease
1 trial -
Dabigatran
BRIGHT MINDS BIOSCIENCES INC.
Mild Cognitive Impairment
1 trial -
Dazucorilant
CORCEPT THERAPEUTICS INC
Hepatic Impairment
1 trial -
Deflazacort
PTC THERAPEUTICS, INC.
Hepatic Impairment
1 trial -
Deflazacort
PTC THERAPEUTICS, INC.
Renal Impairment
1 trial -
EDG-7500
Edgewise Therapeutics
Renal Impairments
1 trial -
EDG-7500
Edgewise Therapeutics
Hepatic Impairment (HI)
1 trial -
ELX-02
Eloxx Pharmaceuticals
Impaired Renal Function
1 trial -
EYP001-110/OP1147
Lacuna Pharma Pty Ltd
Healthy volunteers, Impaired renal function and suspected MASH
1 trial -
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Merck Sharp and Dohme
Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).
1 trial -
Entinostat
Syndax Pharmaceuticals
Renal Impairment
1 trial -
Fazirsiran
Takeda
Hepatic Impairment
1 trial -
First-in-Human Study of RO7812653
Hoffmann-La Roche
Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)
1 trial -
GC4419
Galera Therapeutics
Renal Impairment
1 trial -
GLPG0634
Lakefront Biotherapeutics NV
Renal Impairment
1 trial -
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
Gilead Sciences Pty Limited
Renal Impairment
1 trial -
HSK3486
The First People's Hospital of Lianyungang
Chronic Renal Impairment
1 trial -
Hydrocodone Bitartrate extended-release tablet
Teva Pharma GmbH
Renal Impairment
1 trial -
Hydrocodone bitartrate extended-release tablet
Teva Pharma GmbH
Hepatic Impairment
1 trial -
ISIS 681257
IONIS PHARMACEUTICALS INC
Renal Impairment
1 trial -
IXP
Vertex Pharmaceuticals (Australia) Pty.
Renal Impairment
1 trial -
J3L-MC-EZEH
Eli Lilly Co.
Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment
1 trial -
J3R-MC-YDAH
Eli Lilly Co.
Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
1 trial -
MBX 2109
MBX Biosciences
Renal Impairment
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.